Canaccord Genuity Reiterates Buy Rating on Twist Bioscience

Canaccord Genuity has reiterated its Buy rating on Twist Bioscience Corporation (NasdaqGS: TWST) with a price target of $90. This update came on June 15, 2026, as the stock traded at $76.17.

Other Institutional Activity in Twist Bioscience

Artisan Partners Limited Partnership increased its holdings by 537,572 shares, ending with 6,367,777 shares valued at about $302.6 million. Meanwhile, ARK Investment Management LLC reduced its position by 1,216,762 shares, now holding 6,342,733 shares worth approximately $301.4 million. BlackRock, Inc. cut its stake by 340,610 shares, bringing its total to 5,554,362 shares valued at $263.9 million. EdgePoint Investment Group Inc. made a small addition of 4,530 shares, totaling 5,382,521 shares valued at $255.8 million. Lastly, William Blair Investment Management, LLC reduced its holdings by 684,711 shares, leaving it with 5,269,718 shares worth $250.4 million.

Twist Bioscience Stock Snapshot

Shares of NasdaqGS:TWST traded near $76.17. Twist Bioscience has a market cap of approximately $4.74 billion and a forward P/E ratio of -78.53, indicating it is not currently profitable. The stock has experienced a 52-week low of $23.30 and a high of $80.50. Its 50-day moving average stands at $59.79, while the 200-day moving average is $42.04. The company has a current ratio of 2.70 and a quick ratio of 2.04, with a debt-to-equity ratio of 24.36.

Recent Earnings

Twist Bioscience reported revenue of $409.5 million with a revenue growth rate of 19.3%. However, the company posted a net margin of -19.85% and a return on equity of -18.16%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on August 3, 2026.

Insider Buying and Selling at Twist Bioscience Corporation

Several insiders at Twist Bioscience sold shares recently. On June 8, 2026, CEO Emily Leproust sold 2,265 shares at an average price of $69.84. Senior Vice President Dennis Cho sold 402 shares at the same price, while Paula Green, SVP of Human Resources, sold 884 shares. Chief Accounting Officer Robert Werner sold 1,359 shares at $69.20. Previously, on May 29, 2026, Dennis Cho sold 14,205 shares, which was a planned transaction.

Analysts Set New Price Targets

On June 15, 2026, TD Cowen maintained its Buy rating on Twist Bioscience with a price target of $89. Canaccord Genuity initiated coverage with a Buy rating and a $90 target. Earlier, on June 11, Piper Sandler initiated its Buy rating with an $85 target. The consensus among nine analysts is a strong buy, with a mean target price of $66.67.

About Twist Bioscience

Twist Bioscience Corporation, headquartered in South San Francisco, California, is a company in the healthcare sector, specifically in diagnostics and research. It manufactures and sells synthetic DNA-based products used in various applications, including therapeutics, diagnostics, and data storage. The company is led by CEO Dr. Emily Marine Leproust and employs 979 people.

Bottom Line

Twist Bioscience continues to attract attention from analysts like Canaccord Genuity, which reiterated its Buy rating. The company, trading at around $76.17, has seen significant institutional activity and insider sales. Investors will be watching its upcoming earnings report on August 3, 2026, for further insights into its financial performance.